Compare Monster Beverage Corp (MNST) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Monster Beverage Corp trades at $94.48 (market cap $93.35B), while Regeneron Pharmaceuticals Inc trades at $670 (market cap $70.47B). The key difference: Monster Beverage Corp is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| MNST | REGN | |
|---|---|---|
Market Cap | $93.35B | $70.47B |
Sector | Consumer Staples | Health |
52-Week High | $99.94 | $812.27 |
52-Week Low | $58.75 | $545.46 |
Enterprise Value | $91.65B | $64.42B |
Dividend Yield | — | 0.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
